Facebook
X
LinkedIn
Forward
Expanding the AD Toolb-OX: A New Pathway for Treating Moderate-to-Severe Disease
The management of moderate-to-severe AD remains challenging due to high disease burden and disease heterogeneity, highlighting the need for more broadly targeted therapeutics. The OX40-OX40L pathway has been identified as a potential therapeutic target for improving outcomes in heterogenous disease. To capitalize on the potential treatment benefits of emerging agents in this category, clinicians must be knowledgeable of the role of OX40-OX40L in AD, the clinical efficacy and safety data for emerging OX40-OX40L-targeted agents, and the gaps in current management that contribute to the burden of disease. In this educational activity, leading dermatology faculty address the current gaps in care of AD, the rationale of OX40-OX40L as a therapeutic target, and topline clinical trial efficacy and safety data for emerging agents targeting this pathway.
Target Audience
The educational design of this activity addresses the needs of physicians, nurses, and other advanced practice providers (nurse practitioners and physician associates) in medical practices that specialize in dermatology.
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Describe current gaps in disease management and factors that contribute to a high disease burden.
- Summarize AD pathogenesis, the role of the OX40-OX40L pathway in disease, and the rationale as a therapeutic target.
- Critically analyze the clinical efficacy and safety data for emerging agents that target the OX40-OX40L pathway.
- Gaps in AD Care
- AD Pathogenesis
- OX40- and OX40L-Targeted Therapies
- Looking to the Future of AD Care
|  |
Christopher Bunick, MD, PhD | Emma Guttman-Yasskey, MD, PhD |
This activity is jointly provided by Global Education Group and LivDerm.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and LivDerm. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hours including 0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by educational funding provided by Amgen, Inc.
Disclosure
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Instructions to Receive Credit
In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 70% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved within your Dashboard or Transcript, which you can access at any time.
Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter | Reported Financial Relationship | ||||||
Christopher Bunick, MD, PhD
|
| ||||||
Emma Guttman-Yasskey, MD, PhD | Consulting Fee (e.g., Advisory Board)
AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis, Artax Biopharma, Astria, Boerhinger-Ingelhiem, Bristol Meyers Squibb, Celldex, Centrexion Therapeutics, Connect Biopharm, Coty, DBV, Dualitas Therapeutics, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Galderma, Gate Bio, GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, NUMAB Therapeutics, OTSUKA, Pfizer, Pharmaxis, Proteologix, RAPT, RayThera, Regeneron, Ribon Therapeutics, Sanofi, SATO, Schrödinger, Sitryx, Sun Pharma, Takeda, Teva, TRex Bio, UCB, VRG Therapeutics |
The planners and managers have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at LivDerm have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and LivDerm do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
PC Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
| MAC Mozilla Firefox, Apple Safari, Google Chrome For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above) |